Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
| Previous close | 40.93 |
| Open | 40.93 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 40.93 - 40.93 |
| 52-week range | 36.00 - 44.48 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 8.943B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 20.00 |
| EPS (TTM) | 2.05 |
| Earnings date | N/A |
| Forward dividend & yield | 1.13 (2.77%) |
| Ex-dividend date | 21 Nov 2022 |
| 1y target est | N/A |
- Business Wire
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
PUTEAUX, France, August 31, 2022--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology.1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with en
- Business Wire
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
PUTEAUX, France, March 29, 2022--Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce Isturisa as an effective and well-tolerated oral therapy for patients with Cushing’s disease. Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome,2 a rare and debilitating condition of hypercortisolism that is most commo
